These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25576920)

  • 1. mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.
    Beagle BR; Nguyen DM; Mallya S; Tang SS; Lu M; Zeng Z; Konopleva M; Vo TT; Fruman DA
    Oncotarget; 2015 Feb; 6(4):2088-100. PubMed ID: 25576920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.
    Wilson-Edell KA; Yevtushenko MA; Rothschild DE; Rogers AN; Benz CC
    Breast Cancer Res Treat; 2014 Apr; 144(2):287-298. PubMed ID: 24562770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p21(WAF1) modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia.
    Davies C; Hogarth LA; Mackenzie KL; Hall AG; Lock RB
    Cell Cycle; 2015; 14(22):3602-12. PubMed ID: 26506264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors reduce WB-F344 oval cell viability and migration capability by suppressing AKT/mTOR signaling in vitro.
    Zhang P; Zhu X; Wu Y; Hu R; Li D; Du J; Jiao X; He X
    Arch Biochem Biophys; 2016 Jan; 590():1-9. PubMed ID: 26558695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
    Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
    J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
    Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS
    Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma.
    Patel RP; Thomas JR; Curt KM; Fitzsimmons CM; Batista PJ; Bates SE; Gottesman MM; Robey RW
    Invest Ophthalmol Vis Sci; 2021 Sep; 62(12):16. PubMed ID: 34533562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity.
    Mehrpouri M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M; Bashash D
    Eur J Pharmacol; 2020 May; 875():173050. PubMed ID: 32142770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.
    Haydn T; Metzger E; Schuele R; Fulda S
    Cell Death Dis; 2017 Jun; 8(6):e2879. PubMed ID: 28617441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
    Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D
    Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression.
    Morales CR; Li DL; Pedrozo Z; May HI; Jiang N; Kyrychenko V; Cho GW; Kim SY; Wang ZV; Rotter D; Rothermel BA; Schneider JW; Lavandero S; Gillette TG; Hill JA
    Sci Signal; 2016 Apr; 9(422):ra34. PubMed ID: 27048565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aurora-B and HDAC synergistically regulate survival and proliferation of lymphoma cell via AKT, mTOR and Notch pathways.
    Wang C; Chen J; Cao W; Sun L; Sun H; Liu Y
    Eur J Pharmacol; 2016 May; 779():1-7. PubMed ID: 26638998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia.
    Davies C; Hogarth LA; Dietrich PA; Bachmann PS; Mackenzie KL; Hall AG; Lock RB
    J Biol Chem; 2011 Oct; 286(43):37639-50. PubMed ID: 21903579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mTOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation.
    Sun DF; Zhang YJ; Tian XQ; Chen YX; Fang JY
    Cell Biol Int; 2014 Jan; 38(1):50-63. PubMed ID: 24030871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
    Sutheesophon K; Kobayashi Y; Takatoku MA; Ozawa K; Kano Y; Ishii H; Furukawa Y
    Acta Haematol; 2006; 115(1-2):78-90. PubMed ID: 16424655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
    Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
    Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of targeting endometrial stromal sarcoma cells via histone deacetylase and PI3K/AKT/mTOR signaling.
    Quan P; Moinfar F; Kufferath I; Absenger M; Kueznik T; Denk H; Zatloukal K; Haybaeck J
    Anticancer Res; 2014 Jun; 34(6):2883-97. PubMed ID: 24922651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells.
    Morgan SS; Cranmer LD
    BMC Res Notes; 2014 Nov; 7():812. PubMed ID: 25406429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
    Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
    Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.